BoraLogix

Free Screen

Your clinic may be making an FDA claim that isn't true — and the change probably happened in August.

Five questions. About three minutes. No account, nothing installed.

What happened in July, and what didn't

On 23–24 July 2026 an FDA advisory committee recommended six peptides — including BPC-157 and TB-500 — for the 503A bulks list. A great deal of trade coverage and clinic marketing read that as "FDA clears BPC-157."

That is not what happened. Advisory committee votes are advisory. The FDA still has to run a full rulemaking, and none of the six is presently eligible for compounding.

A clinic that updated its website in August, in good faith, on the strength of that coverage may be making an unapproved drug claim right now.

Separately, the FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Comments closed on 30 July 2026 and the final order is still pending, with no published date. A clinic that finds out when it publishes has already been dispensing on a supply chain that is about to close.

This screen asks the five questions that most often separate a clinic that is fine from one that has a problem it hasn't noticed.

This is not legal or medical advice. This tool does not tell you whether anything you do is legal, and it does not tell you to start, stop or change any clinical practice. It produces a list of things to review with your own attorney and medical director.

Regulation in this area changes constantly. You are responsible for verifying current requirements for your state and your practice. A clean result here is not a defence and is not a finding of compliance.

Five questions

Question 1 of 5 · Peptides

Does your clinic currently stock, dispense, administer or advertise any of these: BPC-157, TB-500, KPV, MOTS-c, Epitalon or Semax?

These are the six peptides the July advisory committee recommended. Include anything sold, offered, listed on a menu, or named on your website or social accounts.

Question 2 of 5 · Claims

Does any of your marketing describe a peptide or a compounded medication as FDA-approved, FDA-cleared, FDA-backed, or as a generic or equivalent of a brand-name drug?

Check your website, intake forms, price lists, email campaigns, and anything an affiliate or influencer says on your behalf. Responsibility for an affiliate's claims sits with the advertiser.

Question 3 of 5 · Compounded GLP-1s

If you dispense compounded semaglutide or tirzepatide: for each patient, is a patient-specific clinical need recorded in the chart?

A documented clinical need is something like a documented allergy to an inactive ingredient, or a dose the branded product does not offer. Cost of the branded drug is not a clinical need.

Question 4 of 5 · Medical direction

In the last 90 days, has your medical director reviewed charts, approved or updated a protocol, or been physically present — with a dated record of it?

The question is not whether you have a medical director. It is whether there is a contemporaneous record showing what they actually did. State boards have been explicit about arrangements where a physician signs a contract but provides no genuine oversight.

Question 5 of 5 · Product sourcing

Could you reconcile your injectable purchase records against your patient administration records — with lot numbers and expiration dates for everything on site?

In April 2026 the FDA issued its first Drug Supply Chain Security Act warning letter to a med spa, after dispensing records showed more product administered than had been purchased from an authorised distributor. Most clinics have never been asked to do this reconciliation.